Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking

Dorothy K. Hatsukami, Stephen Rennard, Manoj K. Patel, Michael Kotlyar, Robert Malcolm, Mitchell A. Nides, Greg Dozier, Matthew P. Bars, Brenda D. Jamerson

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


PURPOSE: To determine whether sustained-release bupropion promotes smoking reduction leading to smoking cessation among persons who wish to reduce their amount of smoking, but who are unwilling to quit or who perceive themselves as being unable to quit. METHODS: Current smokers were assigned randomly to receive either sustained-release bupropion (150 mg twice daily) or matching placebo. During an initial 6-month smoking reduction phase, those who were willing to quit entered a 7-week cessation phase, during which study medication was continued. RESULTS: Four-week continuous abstinence rates were 14% (41/295) in the bupropion group and 8% (25/299) in the placebo group (P = 0.02) during treatment. However, this benefit did not continue after treatment was stopped; subsequent continuous abstinence rates were 7% (20/295) in the bupropion group and 5% (16/299) in the placebo group (P = 0.50). Similar proportions of subjects entered the cessation phase in both treatment groups (38% [n = 113] of those in the bupropion group and 34% [n = 101] of those in the placebo group), although the time until a cessation attempt was shorter for those taking bupropion (median, 64 days vs. 118 days, P = 0.008). The extent of smoking reduction (measured by urinary cotinine concentrations) among the 327 subjects who did not enter the cessation phase was significantly greater (P <0.05) in those treated with bupropion during the reduction treatment phase, but not during the month 12 follow-up visit (P = 0.25). CONCLUSION: Sustained-release bupropion, when used in smokers initially not willing to make a cessation attempt, can help sustain smoking reduction while subjects are on active medication, reduce the time until the next cessation attempt, and increase short-term abstinence rates. However, these benefits were modest and not sustained after bupropion was discontinued.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalAmerican Journal of Medicine
Issue number3
StatePublished - Feb 1 2004

Bibliographical note

Funding Information:
This study was supported by GlaxoSmithKline, Research Triangle Park, North Carolina. The sponsor was responsible for finalizing the design of the study and oversight of the research project, had primary responsibility for conducting the data analyses, and reviewed the final paper.


Dive into the research topics of 'Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking'. Together they form a unique fingerprint.

Cite this